Trisequensa 2 mg FC tablets
PDF Leaflet Revision Date: 01 February 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of symptoms due to estrogen deficiency in postmenopausal women.
Dosage (summary)
One tablet daily, starting with blue tablets for 12 days, followed by white for 10 days, then red for 6 days.
Special Populations
- Elderly
- Renal impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation.
Key Drug Interactions
- Anticonvulsants
- Antibiotics
- St. John's Wort
Contraindications
- Hypersensitivity
- Breast cancer
- Active liver disease
- Thromboembolic disorders
Common side effects
- Vaginal bleeding
- Breast pain
- Nausea
- Headache
Counselling Points
- Take at the same time daily
- Report any unusual bleeding
- Perform monthly breast self-exams
Serious warnings
- Increased risk of breast cancer
- Risk of thromboembolic events
- Monitor for mood changes
Important Disclaimer
The Trisequensa 2 mg FC tablets professional information leaflet below is the property of Novo Nordisk and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
